[Osteoarticular infections: therapeutic proposals of the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP)].
The empiric choice of initial antibiotherapy in osteoarticular infections in infants and children must take into consideration the actual epidemiology of principal pathogens, their respective antibiotic sensitivity profile, their pharmacokinetic and pharmacodynamic properties and the results of efficacy clinical studies. After a review of recent data concerning these four major points, the Paediatric Infectious Diseases Group of the French Society of Paediatrics (GPIP) has proposed guidelines for initial recommended schemes of antimicrobial therapy in acute and non complicated osteoarticular infections in infants and children.
Grimprel
E
E
Groupe de Pathologie Infectieuse Pédiatrique de la Société Française de Pédiatrie, Hôpital Armand Trousseau, 26 av Dr Arnold Netter 75012 Paris, Université Pierre et Marie Curie Paris VI, France. emmanuel.gripmrel@trs.aphp.fr
Lorrot
M
M
Haas
H
H
Pinquier
D
D
Parez
N
N
Ferroni
A
A
Cohen
R
R
D000284:Administration, Oral; D019980:Amoxicillin-Potassium Clavulanate Combination / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D001419:Bacteria / Q000145:classification / Q000187:drug effects; D001424:Bacterial Infections / Q000188:drug therapy*; D001850:Bone Diseases, Infectious / Q000188:drug therapy*; D002648:Child; D017714:Community-Acquired Infections / Q000188:drug therapy; D003428:Cross Infection / Q000188:drug therapy; D024881:Drug Resistance, Bacterial; D024841:Fluoroquinolones / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007592:Joint Diseases / Q000188:drug therapy / Q000382:microbiology*; D017882:Kingella kingae / Q000187:drug effects; D016106:Methicillin Resistance; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects; D016870:Neisseriaceae Infections / Q000188:drug therapy; D010406:Penicillins / Q000627:therapeutic use; D011008:Pneumococcal Infections / Q000188:drug therapy; D025762:Pristinamycin / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000188:drug therapy; D013211:Staphylococcus aureus / Q000187:drug effects; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D024841:Fluoroquinolones; D010406:Penicillins; D025762:Pristinamycin; D019980:Amoxicillin-Potassium Clavulanate Combination; D012293:Rifampin